Clinical trials: Chronic Myelomonocytic Leukemia
Leukemia, Myelodysplastic Syndromes
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00072475
- Testing
- vatalanib
- Where
- 68 sites in United States
- Volunteers
- 155 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia, Myelodysplastic Syndromes
Topotecan in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of topotecan in treating patients who have…
- Trial name
- NCT00003675
- Testing
- topotecan hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Leukemia, Acute Myeloid Leukemia
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
There is no curative therapy once acute leukemia patients relapse after transplant. Patients who develop clinically significant graft versus host disease (GVHD) have a lower rate of relapse than those who do not develop GVHD.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia
- Trial name
- NCT01036009
- Testing
- Withdrawal of immunosuppression and donor lymphocyte infusion
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Chronic Myelomonocytic Leukemia
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
The primary objective of this study is: Response to treatment will be evaluated according to the revised International Working Group (IWG) categories natural history, hematologic improvement and cytogenetic response1;2.
- Trial name
- NCT01350947
- Testing
- 5-Azacitidine
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
This research study is studying identification of de novo Fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01146210
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Leukemia
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
The goal of this clinical research study is to learn if 5-azacitidine and sorafenib can control the disease in patients with AML or MDS. The safety of this drug combination will also be studied.
- Trial name
- NCT01254890
- Testing
- Azacitidine, Sorafenib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelomonocytic, Chronic, Leukemia-Lymphoma
Korean Post-marketing Surveillance for Sprycel®
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory…
- Trial name
- NCT01464047
- Where
- South Korea
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Sorafenib in Myelodysplastic Syndrome
The purpose of this study is to evaluate the efficacy of sorafenib in patients with Myelodysplastic Syndrome (MDS). Eligible subjects will receive Sorafenib administered at 400mg orally twice a day, given on days 1-28 of a 28-day…
- Trial name
- NCT00510289
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage.
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT01398462
- Testing
- CWP232291
- Where
- 5 sites in United States, South Korea
- Volunteers
- 69 people
- Sponsor
- JW Pharmaceutical
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemias, Acute Myeloid Leukemia (AML)
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous…
- Conditions
- Leukemias, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Adult T Cell Leukemia (ATL)
- Trial name
- NCT00664677
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Erimos Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00014495
- Testing
- filgrastim, cytarabine, bismuth Bi213 monoclonal antibody M195
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
MDS, AML
Non-interventional Study With Azacitidin (Vidaza®)
The purpose of this non-interventional study is to collect data on the efficiency and safety of Azacitidin in the routine application.
- Conditions
- MDS, AML, CMMOL
- Trial name
- Piaza (NCT01192945)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- iOMEDICO AG
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
The goal of this clinical research study is to learn if clofarabine given by mouth on a weekly schedule can help to control MDS. The safety of clofarabine given by mouth will also be studied.
- Trial name
- NCT00299156
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors, Leukemia
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
RATIONALE: Gathering information about why patients or their guardians agree or decline to participate in the optional pharmacokinetic portion of a phase I treatment study may help doctors plan clinical trials in the future.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00890435
- Testing
- questionnaire administration, psychosocial assessment and care
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins